Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
CLINICAL MANIFESTATIONS AND LABORATORY DIAGNOSIS OF
BRONCHOPULMONARY DYSPLASIA IN NEWBORN INFANTS
Furqat Mukhitdinovich Shamsiev
Head of the Pulmonology Department, Doctor of Medical Sciences (D.Sc.), Professor
Republican Specialized Scientific-Practical Medical Center of Pediatrics
Ministry of Health of the Republic of Uzbekistan
Ra’no Anvarbekovna Musajanova
Leading Scientific Researcher, Doctor of Medical Sciences (D.Sc.)
Pulmonology Department, Republican Specialized Scientific-Practical Medical Center of
Pediatrics
Ministry of Health of the Republic of Uzbekistan
Shamsiya Sokhibnazarovna Ismoilova
Email:
Assistant, Department of Propaedeutics of Childhood Diseases, Pediatric Diseases and
Family Medicine
Tashkent Medical Academy, Termiz Branch
Haydarkul Sokhibnazarovich Khudoynazarov
Neurologist
Sharghun Central Polyclinic, Sariosiyo District, Surkhandarya Region
Annotation:
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that primarily
affects premature newborns who have received prolonged oxygen therapy or mechanical
ventilation. The aim of this article is to analyze the clinical manifestations and laboratory
diagnostic methods of BPD in neonates. Early diagnosis of BPD is crucial for improving
outcomes and minimizing complications. The study highlights key clinical signs such as
respiratory distress, oxygen dependency, and poor weight gain, as well as the role of chest
radiography, blood gas analysis, and inflammatory markers in establishing the diagnosis.
Understanding the clinical-laboratory profile of BPD facilitates timely intervention and
guides treatment strategies, ultimately contributing to better prognosis in affected infants.
Keywords:
Bronchopulmonary dysplasia, newborn, prematurity, respiratory distress,
oxygen therapy, mechanical ventilation, clinical signs, laboratory diagnosis, blood gas
analysis, neonatal care.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Introduction.
Bronchopulmonary dysplasia (BPD) is one of the most common and challenging chronic
pulmonary diseases seen in neonatology, primarily affecting premature infants, particularly
those born before 32 weeks of gestation and with very low birth weight. BPD develops as a
result of lung immaturity combined with various postnatal insults, such as prolonged
mechanical ventilation, high concentrations of oxygen, infections, and inflammation. These
factors contribute to arrested lung development, impaired alveolarization, and abnormal
vascular growth, ultimately resulting in long-term respiratory complications. Despite
advancements in perinatal care, the incidence of BPD has not significantly declined due to
increased survival rates of extremely preterm infants. Therefore, early recognition and
diagnosis of BPD are critical for implementing timely therapeutic interventions aimed at
minimizing respiratory morbidity and improving quality of life. The clinical course of BPD
is often characterized by persistent oxygen dependency beyond 28 days of life, tachypnea,
retractions, and recurrent episodes of respiratory distress. Laboratory diagnostics play an
important role in confirming BPD and differentiating it from other pulmonary conditions in
neonates. Key investigations include blood gas analysis, markers of inflammation, imaging
techniques such as chest X-rays, and in some cases, echocardiography to assess associated
pulmonary hypertension. This article provides a comprehensive overview of the clinical and
laboratory characteristics of bronchopulmonary dysplasia in newborn infants, aiming to
enhance understanding and support improved clinical management of this vulnerable patient
population.
Main Body.
1. Etiology and Risk Factors
Bronchopulmonary dysplasia (BPD) is a multifactorial disease that results from a
combination of prenatal and postnatal factors. Major risk factors include prematurity, low
birth weight, prolonged mechanical ventilation, supplemental oxygen therapy, intrauterine
growth restriction, and perinatal infections. The immature lungs of preterm infants are
highly susceptible to injury, and the use of life-saving respiratory support can paradoxically
contribute to lung damage. Antenatal exposure to inflammation or chorioamnionitis and
postnatal sepsis also play critical roles in the development of BPD.
2. Pathophysiology
The hallmark of BPD is impaired alveolar and pulmonary vascular development. In classical
BPD, seen in older infants, lung injury led to fibrosis and inflammation, whereas the "new"
BPD observed in extremely preterm infants is characterized by fewer and larger alveoli with
minimal fibrosis. Inflammatory processes, oxidative stress from oxygen toxicity, volutrauma
and barotrauma from mechanical ventilation, and disrupted signaling for normal lung growth
all contribute to disease progression.
3. Clinical Manifestations
Clinical signs of BPD vary depending on the severity of the condition. Typically, BPD is
suspected in infants who remain dependent on supplemental oxygen for more than 28 days
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
after birth. Common symptoms include: Persistent tachypnea and respiratory distress.
Intercostal and subcostal retractions, Nasal flaring and grunting, Poor weight gain, Cyanosis
or desaturation episodes. Increased susceptibility to respiratory infections. BPD is classified
based on the severity at 36 weeks postmenstrual age (PMA) or discharge:Mild: breathing
room air at 36 weeks PMA Moderate: need for <30% oxygen. Severe: need for ≥30%
oxygen and/or positive pressure support
4. Laboratory Diagnosis.
Accurate and early diagnosis of BPD relies on a combination of clinical criteria and
laboratory assessments: Blood Gas Analysis: Hypoxemia and hypercapnia are common
findings, with respiratory acidosis in severe cases. Complete Blood Count (CBC): Elevated
white blood cell count may indicate ongoing inflammation or infection. C-reactive Protein
(CRP) and Procalcitonin: Useful for ruling out concomitant sepsis or systemic inflammatory
response. Chest Radiography: Provides visual confirmation of lung changes. Classic
findings include hyperinflation, atelectasis, and areas of fibrosis or cystic changes. Pulse
Oximetry: Monitoring oxygen saturation helps assess the need for supplemental oxygen and
track disease progression. Echocardiography: Often used to evaluate pulmonary
hypertension, which is a frequent complication of moderate to severe BPD.
5. Differential Diagnosis
It is important to differentiate BPD from other neonatal respiratory disorders such as
neonatal pneumonia, congenital lung malformations, transient tachypnea of the newborn,
and meconium aspiration syndrome. A thorough clinical evaluation combined with
laboratory and imaging findings is essential for accurate diagnosis.
6. Management Overview (Brief)
Although the focus of this article is diagnosis, it is worth noting that BPD management
involves a multidisciplinary approach. Supportive care, judicious use of oxygen,
optimization of nutrition, use of diuretics, corticosteroids in select cases, and prevention of
infections are central to therapy. Long-term follow-up is also critical to address
developmental, respiratory, and neurological outcomes.
Conclusion:
Bronchopulmonary dysplasia remains a significant cause of morbidity among preterm
infants, especially those requiring prolonged respiratory support. Understanding its
multifactorial etiology and recognizing early clinical and laboratory indicators are essential
for prompt diagnosis and effective management. Persistent oxygen dependency, respiratory
distress, and poor postnatal growth are key clinical signs, while laboratory assessments such
as blood gas analysis, inflammatory markers, and chest imaging play a pivotal role in
confirming the diagnosis. Timely identification of BPD enables early intervention strategies
that can improve respiratory outcomes, reduce complications, and enhance the quality of life
for affected neonates. Continued research and advancements in neonatal care are necessary
to further reduce the incidence and severity of BPD in vulnerable populations.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
References:
1. Jobe, A.H., & Bancalari, E. (2001). Bronchopulmonary dysplasia. American Journal of
Respiratory and Critical Care Medicine, 163(7), 1723–1729.
2. Thébaud, B., Goss, K.N., Laughon, M., Whitsett, J.A., Abman, S.H., Steinhorn, R.H., &
Aschner, J.L. (2019). Bronchopulmonary dysplasia. Nature Reviews Disease Primers, 5(1),
1–23.
3. Bancalari, E., & Jain, D. (2019). Bronchopulmonary Dysplasia: Can We Agree on a
Definition? American Journal of Perinatology, 36(S02), S110–S113.
4. Ismoilova, S.S. (2022). Neonatal pneumonias and bronchopulmonary dysplasia: clinical
cases and laboratory indicators. Scientific Bulletin of Tashkent Medical Academy, 1(4), 55–
59.
5. Davis, P.G., Morley, C.J., & Owen, L.S. (2018). Diagnosis and management of BPD in
preterm infants: an update. Seminars in Fetal and Neonatal Medicine, 23(3), 227–235.
6. Rakhmonova, M. (2021). Respiratory distress syndrome in the neonatal period and its
consequences. Journal of Pediatrics and Neonatology, 2(2), 43–48.
7. Northway, W.H., Rosan, R.C., & Porter, D.Y. (1967). Pulmonary disease following
respirator therapy of hyaline-membrane disease: bronchopulmonary dysplasia. The New
England Journal of Medicine, 276(7), 357–368.
8. Khakimova, N. (2020). Laboratory diagnostics and clinical approaches in pulmonary
pathologies. Journal of Medical Research, 3(5), 72–76.
9. Abman, S.H., Collaco, J.M., Shepherd, E.G., Keszler, M., Cuevas-Guaman, M., Welty,
S.E., & Truog, W.E. (2017). Interdisciplinary care for infants with severe bronchopulmonary
dysplasia. The Lancet Respiratory Medicine, 5(10), 872–883.
10. Yunusova, Z. (2023). The role of early diagnosis and care in the prevention of
bronchopulmonary dysplasia. Journal of Medical Practice and Innovations, 1(1), 31–35.
